| Test | Patients tested n | |
| FVC % pred | 61 | 90±18 (47–125) |
| FEV1 % pred | 61 | 80±21 (33–123) |
| Post-bronchodilator improvement in FEV1 L | 36 | 0.06±0.13 (-0.35–0.3) |
| FEV1/FVC % | 61 | 69±13 (30–94) |
| FEF25–75% % pred | 57 | 51±26 (15–118) |
| TLC % pred | 56 | 88±17 (44–132) |
| RV % pred | 56 | 90±32 (35–188) |
| DLCO % pred | 57 | 37±16 (10–80) |
| KCO % pred | 57 | 46±19 (8–84) |
| PaO2 at rest (surpine position) kPa | 61 | 8.4±1.9 (4.6–13.3) |
| PaCO2 at rest (surpine position) kPa | 61 | 4.9±0.7 (3.0–7.3) |
| Alveolar–arterial PaO2 difference (room air) kPa | 61 | 5.5±2.1 (0.1–11.7) |
| PaO2 at exercise–PaO2 at rest (surpine position) kPa | 22 | -1.5±1.6 (-4.4–1.7) |
| 6-min walking distance m | 23 | 336±139 (50–548) |
| Decrease in SpO2 during 6-min walk test % | 23 | -8.9±5.7 (-20–0) |
Data are presented as mean±sd (range), unless otherwise stated. FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s; FEF25–75%: mean forced expiratory flow between 25% and 75% of FVC; TLC: total lung capacity; RV: residual volume; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: transfer coefficient of the lung for carbon monoxide; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; SpO2: arterial oxygen saturation measured by pulse oximetry. Reproduced from [4].